One of the main goals in allogeneic bone marrow transplantation is the abrogation of graft-versus-host disease with the preservation of antileukaemia and antiviral activity. We have established a novel system for the selective removal of alloreactive lymphocytes from donor grafts while retaining an effective allogeneic response to third-party stimulator cells. Initial feasibility studies were done with unrelated HLA-mismatched pairs and then extended into the matched setting. Mononuclear cells from HLA-matched donors were cocultured with irradiated recipient cells prestimulated with cytokines (␥-IFN and TNF-␣) in a modified mixed lymphocyte culture (MLC). Alloreactive donor lymphocytes were identified by expression of CD69, an early activation marker and selectively removed by paramagnetic bead sorting. The remaining 'non-alloreactive' lymphocytes were tested in proliferative assays against the original matched recipient and to a third-party donor. A mean depletion of proliferative capacity to 11.5 ؎ 9.9% of the original matched recipient response was achieved while the residual third-party response was largely preserved at 77.8 ؎ 20.9% which should translate into improved immune reconstitution and preservation of antiviral activity. The non-alloreactive lymphocytes could also possess functional antileukaemia activity. Moreover, the alloreactive cells are easily recoverable in this selective T cell depletion strategy for cryopreservation and ready for immediate access as therapeutic donor lymphocyte infusions in cases of frank relapse post transplant.
successful in reducing the incidence and severity of acute and chronic GVHD; 3 unfortunately, they have been associated with a concomitant rise in the incidence of graft rejection, leukaemia relapse and delayed immunological reconstitution. [4] [5] [6] [7] So far, successful use of T cell depletion has required the establishment of an appropriate balance between the residual immune response of the recipient, which can be achieved by enhanced conditioning, and the adjustment of the T cell content of the donor bone marrow. 8, 9 That T cells play an integral role in the mechanisms of graft rejection, GVHD and in GVL activity is no longer in doubt. What has proved to be more difficult has been the identification of specific subsets of cells involved in each of these activities. Murine models have variously implicated either CD4 ϩ or CD8 ϩ cells as effectors in GVHD. 1, 10 These observations have been strain-specific and dependent on the degree of donor-recipient histocompatibility. They have also not translated as clearly into the human situation. Similarly, CD4 ϩ , CD8 ϩ and NK cells have all been implicated in GVL activity without causing GVHD, [11] [12] [13] these however may only be applicable to certain leukaemias and not others. 14 The advent of donor leucocyte infusion (DLI) has provided the strongest evidence so far of the importance of a GVL effect, 15, 16 and again attempts have been made to identify distinct populations of cells involved in GVL without inducing GVHD. 17, 18 An alternative approach to pan T cell depletion is to selectively deplete only those T cell subsets responsible for graft-versus-host reactions while retaining lymphocytes capable of GVL and antiviral activity in the graft. [19] [20] [21] [22] [23] Immune recovery may also be improved with the increased numbers of residual T cells in the graft leading to a more diverse repertoire.
Here we present a selective T cell depletion strategy based upon the physical separation of the alloreactive T cells from the donor graft whilst retaining the non-alloreactive T cells. In this system donor T cells were stimulated in vitro with recipient mononuclear cells (representing alloreactive GVHD targets). After defined periods, alloreactive responder cells were identified by virtue of their expression of an activation marker and then physically depleted from the remaining cells using magnetic cell sorting (MACS, Miltenyi Biotec, Cologne, Germany).
We have chosen to use CD69 as the activation marker in this study. This antigen is a type II integral membrane protein belonging to the family of C-type lectin receptors. 24 It is one of the earliest cell surface activation markers that is expressed on lymphocytes and NK cells after mitogenic stimulation. Upregulated CD69 expression on T lymphocytes may be followed by cell proliferation and an increase in secretion of IL-2 and IFN-gamma. 25 The kinetics for the expression of CD69 have been investigated by us and previously published. We have shown that CD69 is upregulated in an allogeneic MLC in a time-dependent fashion, 26 peaking at 96 h and could be used as a marker of alloreactivity and indirectly of GVHD.
Materials and methods

Patients and subjects
In the initial feasibility study involving mismatched pairs, blood was obtained from HLA mismatched normal volunteer donors. For the matched study, the first-party stimulators were patients (recipients) who were undergoing subsequent HLA-matched allogeneic bone marrow transplants. The responders (donors) were either their HLA-identical siblings or matched unrelated donors from a donor registry (Anthony Nolan Research Centre or Bristol Bone Marrow Registry). Peripheral blood was collected from the donors and remission peripheral blood or bone marrow from the patients after informed consent. For the third-party stimulators, blood was collected from HLA-mismatched normal volunteer donors.
The mononuclear cell fraction (MNC) was isolated from heparinised blood or bone marrow by density gradient centrifugation (Lymphoprep, Nycomed Pharma, Oslo, Norway), washed in RPMI 1640 and supplemented with 10% fetal calf serum (FCS), 2.5 mm l-glutamine and 100 units/ml penicillin and streptomycin (complete medium (CM), all from Gibco, Paisley, UK). All cell densities were adjusted to 10 6 cells/ml. Cells were either used fresh or cryopreserved in N 2 vapour for subsequent use.
HLA typing
In each case, donor and recipient pairs were serologically typed for HLA-A and HLA-B locus antigens and high resolution sequence specific oligonucleotide typing for HLA-DRB1, DRB3, DRB4, DRB5 and DQB1 alleles (performed at the Anthony Nolan Research Centre, London, UK).
Identification and selection of alloreactive T cells
HLA-mismatched study: In each case, PBMC from three unrelated normal donors were used; one termed the responder population, one the first-party stimulator population and one as the third-party stimulator to assess specificity of alloreactive cell removal. Responder PBMC were mixed in an equal ratio with irradiated first party stimulator cells in a one-way 'primary mixed lymphocyte culture' (MLC). In a parallel culture, responder cells were also mixed in an equal ratio with an irradiated third-party population. All cells were resuspended to a density of 10 6 cells/ml and cultured in tissue grade plastics (Nunclon, Nunc, Denmark).
The controls for each experiment were non-stimulated responder cells alone. All stimulator cells were irradiated for a total of 33 Gy just prior to mixing. The 'primary MLCs' were incubated at 37°C/5% CO 2 and samples analysed at 72-96 h for CD69 expression in the responder population. Using analysis by flow cytometry (FACScan with Lysis II software, Becton Dickinson, Oxford, UK), responder lymphocytes and lymphoblasts were easily identified by live gating on forward angle light scatter (FSC) and side angle light scatter (SSC) signals. By 72 h, the irradiated stimulator cells had moved out of this lymphoid gate due to apoptosis and could be easily separated from the responder population (Figures 1 and 2 ).
CD69 expression was assessed for the responder population in both the first-party primary MLC and the thirdparty primary MLC. Alloreactive cells in the first-party primary MLC could be distinguished from non-alloreactive cells by the expression of CD69. These CD69ϩve cells in the first-party primary MLC were then depleted using a magnetic cell sorting (MACS) AS depletion column (Miltenyi Biotec). This is a sterile technique of cell separation involving the passage of cells labelled with iron dextran microparticles (50 nm diameter) through a ferrous matrix column within an intense magnetic field. Cells were labelled with saturating amounts of anti-CD69 FITC for 10 min as described by the manufacturers. Excess antibody was then washed off before incubation with anti-FITC microbeads for 30 min at 4-8°C after which the labelled cells were passed down an AS column with a 25 G capillary. The buffer used throughout the separation procedure was Dulbecco's phosphate-buffered saline (PBS) supplemented with 2 mm EDTA and 0.5% BSA (MACS buffer). Non-bound cells were collected and termed the 'depleted fraction'. After briefly washing the column with MACS buffer, the bound cells were eluted by forced flushing of the column outside the magnetic field. The eluted cells were termed the 'enriched fraction'.
The CD69-depleted responder PBMC were then re-introduced with equal numbers of first-party stimulator PBMC in a first-party secondary MLC. The depleted fraction was also mixed in a parallel culture with equal numbers of the same third-party PBMC in a third-party secondary MLC. CD69 expression of the responder population in both secondary MLCs were then assessed at the same time-point prior to sorting as in the primary MLC.
The CD69 expression of the unsorted cells against either first-party stimulator or third-party was normalized to 100%, and the degree of depletion achieved determined by the following formula:
(CD69 expression in primary MLC) Ϫ (CD69 expression in responder alone) ϫ 100% (CD69 expression in secondary MLC) Ϫ (CD69 expression in depleted fraction alone)
The degree of depletion to both the first-party stimulator and the third-party was then compared as a percentage of the unsorted response. Figure 3 outlines the method in a flow diagram. The same procedure was applied as above with the patient being the first-party stimulator and the matched donor (either sibling or unrelated) being the responder. However, to circumvent the problem that no appreciable CD69 expression or tritiated thymidine ( 3 HTdR) uptake is normally detected above baseline in HLA matched pairs (data not shown), the following modifications to the above procedure were made: (1) Modified MLC: All stimulator cells (PBMC from patient, third-party donor and the autologous control) were pretreated with 1000 U/ml of ␥-IFN (Genzyme, West Malling, Kent, UK) and 1000 U/ml of TNF-␣ (Genzyme) for 24 h. The cytokines were washed off twice with PBS and resuspended in CM at 10 6 cells/ml. The stimulator cells were then irradiated for a total of 33 Gy before being mixed with the donor (responder) cells. To exclude any non-specific effect by the cytokines, an autologous control was set up in parallel consisting of responder cells mixed with cytokine pretreated autologous cells. as an in vitro marker of alloreactivity to compare the results of depletion in matched pairs. In addition to assessing the CD69 expression at 72-96 h, proliferation assays were set up in triplicate in 96-well round-bottom plates using 10 5 donor (responder) and 10 5 cytokine pretreated irradiated patient (first-party stimulator) or third-party cells per well in a total volume of 200 l/well. 18 U/ml of IL-2 or 1000 U/ml of IL-4 (Genzyme, West Malling, Kent, UK) were added to this modified MLC. The baseline autologous controls were donor cells plus cytokine pretreated autologous stimulators. The other controls present were irradiated stimulators alone. Cultures were incubated at 37°C/5% CO 2 for 5 days, and pulsed for the last 18 h with 1 Ci/well of 3 HTdR. Cells were harvested and tritiated thymidine incorporation measured in a Wallac 1205 Betaplate (Wallac, Turku, Finland). Proliferation was measured for both the primary first and third party MLCs. After removal of alloreactive cells via the AS column, proliferation assays were again set up for the depleted fraction in the secondary HLAmatched and third party MLC. The specificity of depletion was assessed by comparing the proliferation assays of the depleted fraction against the pre-sorted cells.
HLA-matched pair study:
The 3 HTdR incorporation of the unsorted cells against either patient (first-party stimulator) or third party was nor-malized to 100%, and the degree of depletion achieved established from the following formula:
From Figure 3 , the relevant calculation is (C)/(A) and (D)/(B). The 3 H-thymidine incorporation in each instance was worked out as the mean of the triplicates.
Cell recovery, purity and depletion efficiency: The responder cell population was counted before and after sorting via the MACS columns. The responder cells could be easily distinguished from irradiated stimulator cells by cell morphology. Responder cells retained their cell shape and nuclear configuration whereas irradiated stimulator cells had lost their membrane and nuclear integrity.
Cell recovery (yield) was calculated as follows:
Number of CD69 neg responder cells post-sorting Number of CD69 neg cells before sorting ϫ 100.
Cell purity of the engineered graft is defined as (100 -%CD69 pos cells in the depleted fraction). Depletion efficiency was calculated by comparing the number of CD69-positive cells in the depleted fraction after sorting with the number of CD69-positive cells prior to sorting. This is expressed as follows: seen that following the depletion strategy, the increase in CD69 expression for the first party stimulator MLC falls from 6 Ϯ 2.4% to 1.5 Ϯ 1.2% while that that of the third party MLC is well maintained at 3.9 Ϯ 2.7% in the first MLC and 4 Ϯ 2.4% in the second MLC.
Results
HLA-mismatched pairs
Selective depletion: To calculate the degree of selective depletion, the primary response for both first party stimulator and third party was normalized to 100% and the residual response expressed as a percentage. The mean residual response post-CD69 depletion was 25.6% Ϯ 17.9. The response to third party stimulator cells was retained (mean of 115.7% Ϯ 35.9) (Figure 4 ). The median cell recovery was 72.5% (range 65-75%) with an associated median purity of 97% (range 96-98%).
The depletion efficiency was a median of 75% (range 65-84%).
Matched pairs
Modified MLC: Following cytokine pre-treatment of stimulator PBMC, proliferative responses were detected in five out of nine HLA-matched pairs. Table 2 shows the 3 Hthymidine incorporation by each of the nine donor-recipient pairs in the primary MLC.
All stimulator cells were cytokine pre-treated as described above. We also assessed the background autologous MLC, ie donor PBMC plus cytokine pre-treated auto- logous PBMC to control for possible non-specific effect from the cytokines.
As detailed in Table 2 , the addition of cytokines to the modified MLC did not cause a significant increase in the autologous MLC compared to the responder cells incubated alone (P Ͼ 0.1). In contrast, the majority of MLC of the matched donor-recipient pairs did generate a proliferative response above that of the autologous control. The trend in all nine experiments for the MLC response was: third-party MLC Ͼ matched donor-recipient MLC Ͼ autologous MLC Ͼ responder alone. This is in keeping with the greater degree of HLA disparity between donor and third party as compared to the matched recipient.
When Bishara et al 27 developed the modified MLC as a predictive tool for clinical GVHD, the relative response index (RRI) was used to calculate if the modified MLC response in the matched pair was positive compared to the autologous control. Normalizing the response against third party as 100%, the relative response index (RRI) was calculated as follows: A relative response index Ͼ5% was considered positive. Table 2 shows the RRI calculated for each experiment: Using the modified MLR, five positive responses were generated out of nine matched pairs (56%).
Effect of cytokines on CD69 expression after HLA-matched MLC:
We have previously established the expression of CD69 in an allogeneic setting and confirmed this in our mismatched study. Initial work done with matched pairs without the use of cytokines showed no upregulation of CD69 expression (data not shown). Like the proliferation seen in the modified MLC, adding cytokines to the system did cause upregulation of CD69 expression in the matched pairs. The difference was that there was an upregulation of CD69 in all pairs tested compared to five out of nine for the proliferative assay ( Table 3) . The mean baseline CD69 activation of the autologous control at 72 to 96 h was 5.0 Ϯ 2.5%, that of matched pairs 8.9 Ϯ 3% and third party was 10.1 Ϯ 4.1%. The mean increase in CD69 expression above autologous control for matched pairs was 3.8% and that of third party controls was 5.1% above baseline. This increase in CD69 expression for mismatched third party using cytokines compared well with the data for the mismatched study. Pre-treatment of stimulator cells with ␥-IFN and TNF-␣ and addition of low dose IL-2 did not increase the baseline CD69 activation of the autologous controls. In contrast, an appreciable CD69 response with matched siblings was generated above the baseline controls. Table 4 shows the results of magnetic cell sorting using the AS depletion columns. This gave a median depletion efficiency of 80.3% (range 62-98.6%). The cell purity was consistently more than 94% (range 94.3-99.8%). As the columns used were designed for depletion strategies, not surprisingly, the enrichment process was less stringent ranging from 30 to 68% CD69-positive cells in the alloreactive enriched fraction.
Depletion efficiency and cell purity:
Recovery of cells:
The median cell recovery was calculated as described in Materials and methods and was 75% with a range of 46-85%.
Selective depletion of alloreactive cells:
In five out of nine experimental pairs (1, 2, 3, 7 and 8), a positive proliferative result was obtained in the modified MLC. We could therefore compare the 3 H-thymidine incorporation of the PBMC before and after depletion. In the other four experiments however, we could not assess the degree of selective depletion of alloreactive cells since no proliferative response was generated in the primary MLC. Nevertheless, in all cases, we were able to determine whether the third party response had been preserved despite the removal of CD69-positive cells after allostimulation. Table 5 shows the 3 H-thymidine incorporation of the five evaluable pairs post-depletion. The residual response was calculated as described in Materials and methods. A mean depletion of proliferative capacity to 11.5 Ϯ 9.9% of the original first party response was achieved ( Figure 5 ). The RRI (Table 5 ) of the depleted fraction is Ͻ5% in each instance which is below the threshold reported to be predictive of clinical GVHD. 27 Preservation of third party response: We looked at the residual third party response to determine if the depletion of alloreactive CD69-positive cells was alloantigen-specific. This showed a mean preservation of proliferative response of 77.8% Ϯ 20.9% as illustrated in Figure 5 . Table 2 shows the relationship between the results of the modified MLC and the incidence of clinical GVHD in the recipients who have undergone an allogeneic transplant from their HLAmatched donor. All sibling transplants (six patients) were non-T cell-depleted (TCD) and recipients were given either cyclosporin or cyclosporin and methotrexate as GVHD prophylaxis. Two patients who had matched unrelated transplants received Campath 1-M ex vivo TCD marrows for GVHD prophylaxis with no additional immunosuppressive therapy. Both also received Campath 1-G prior to transplant as part of the conditioning treatment. The ninth donor-recipient pair did not proceed on to a transplant. As shown in Table 5 , a RRI Ͼ5%, indicating a positive modified MLC was associated with subsequent clinical GVHD in three of four evaluable patients. Only one of the four patients receiving a bone marrow from a donor showing a RRI Ͻ5% (ie negative) showed evidence of clinical GVHD post transplant. The median follow-up period of these patients is 12 months (range 8-13 months).
Association with clinical GVHD:
Discussion
GVHD still represents a major barrier to successful allogeneic transplantation. Pan T cell depletion strategies have reduced the incidence and severity of GVHD. Unfortunately, this has not generally translated into better survival rates largely due to reported increased rates of leukemia relapse, graft rejection and infections from delayed immune reconstitution. The increase in patients requiring allogeneic BMT has also meant that, in many cases, no fully matched donor is available. Use of mismatched or haploidentical donors is associated with an even higher incidence of clinically significant GVHD and more impaired immune reconstitution. The T cell depletion strategy we have described here preferentially removes cells recognising GVHD targets by in vitro stimulation of donor cells with cytokine-treated irradiated recipient PBMC and the subsequent selection of alloreactive cells on the basis of CD69 expression. By removing the CD69-positive cells via a MACS column, we have shown that it is possible to deplete approximately 90% of the alloreactive component while maintaining Ͼ70% of the residual immunity as measured by a third party alloantigen response. The selective depletion of cells may increase haematopoietic engraftment rates post transplant. It has been shown that T cells of donor origin, devoid of anti-recipient activity, may contribute to engraftment by the production of cytokines or by the exertion of a veto effect on host CTLs. 20 We also expect enhanced immune reconstitution since this has been shown to be directly proportional to the number of T cells in the infused graft. 8 This method may also exploit antigen differences on normal tissues and leukaemia cells in that donor responses to recipient MHC and ubiquitous mHA are eliminated while conserving responses to lineage-restricted or even leukaemia-specific antigens. This would translate into a graft-mediated antileukaemia activity.
CD69 was chosen as the activation marker because it is expressed on the cells of interest in GVHD-activated T and NK cells. It is upregulated as early as 24 h after allogeneic stimulation and peaks at 96-120 h. 26 CD69 was expressed at sufficiently high density on activated cells for efficient removal by the MACS device. Lamb et al 28 have found a good correlation between CD69 expression and 3 H-thymidine incorporation in the evaluation of T cell function. Other studies have also shown good correlation in the CD69 and proliferative response to various mitogenic stimuli. 29 Various groups have used immunotoxins or fluorescent activated cell sorting (FACS) to eliminate activated cells, identified by expression of CD25. [19] [20] [21] [22] [23] The use of immunotoxins however results in the loss of the activated alloreactive cells. It also requires the manufacture and use of immunotoxins for clinical use. FACS sorting on the other hand is slow and designed for positive selection rather than depletion strategies.
We believe this method of selective depletion has several advantages over other protocols in that: (1) The alloreactive cells are easily recoverable and can be cryopreserved for ready immediate access as DLI if the patient relapses. This could be of particular value in the treatment of relapsed acute leukaemias, especially if donor availability and recall is a problem. (2) The MACS columns enable a good median depletion efficiency to be achieved (80.3%). (3) The use of immunomagnetic bead columns is already in clinical use for CD34 selection.
We are aware that these alloreactive cells have the potential for causing GVHD, and its use may therefore not extend to relapsed patients having only minimal residual disease on board. However, in frank relapses where the urgency of treatment is a priority, this strategy can be particularly useful. Moreover, the results of conventional DLI have been disappointing in the treatment of relapse of ALL where the GVL effect is less marked 10 and attainment of remission may be dependent on an alloreactive cell strategy like ours.
The method of selective depletion has also proved to be efficient in cell recovery (75%). The depleted fraction demonstrated good cell purity (range 94-99.8%) and is an easy and sterile system to use which can be readily translated into clinical use.
It is well established that in an HLA-matched setting, a conventional MLC is non-reactive and unable to detect minor antigenic differences that exist. Minor histocompatibility antigens (mHA) are the main source of disparity between HLA-matched siblings and contribute a significant part to the antigenic disparity between HLA-matched but unrelated pairs. mHA are thought to be derived from normal but polymorphic cellular proteins which are presented by MHC molecules and recognised in a MHC restricted fashion. 30 Bishara et al 27 have demonstrated that pre-treatment of stimulator cells with cytokines and the subsequent addition of cytokines to the MLC can detect fine antigenic disparities that exist between HLA-identical siblings. Our data supported this. In five out of nine pairs (three sibling, two unrelated), a positive MLC was generated while four (three sibling, one unrelated) remained negative despite the addition of cytokines. Furthermore, the results of the modi-fied MLC were, in general, predictive of the incidence of clinical GVHD following transplantation. Although numbers are small, this does imply some clinical association and a negative modified MLC may predict absence of GVHD. It is equally encouraging that our method of alloreactive cell removal has depleted the response to below the predictive threshold for clinical GVHD (RRI Ͻ5%).
It has been shown that TNF-␣ and ␥-interferon can increase the expression of class I and II molecules on GVHD target tissue as well as adhesion molecules important in cell-cell signaling. 31, 32 Pre-treatment of stimulator PBMCs with cytokines did increase the expression of these molecules (data not shown) and this could have increased the number of rare MHC/peptide combinations above the threshold necessary for T cell stimulation. Upregulation of adhesion and costimulatory molecules could also reduce the threshold for T cell activation and thus account for the positive reactions seen in the modified MLC. 33 This is also relevant in the clinical situation where cytokines have been implicated in the pathogenesis of GVHD, the socalled 'cytokine storm'. 34, 35 In terms of CD69 expression, the addition of cytokines did not induce any non-specific increase above the baseline controls. The matched pairs and third-party MLCs showed a significant increase in CD69 expression above background. Interestingly, the CD69 expression in the modified (with cytokines) third-party MLCs and autologous controls were no higher than in the simple third party and control MLCs (without cytokines) in our mismatched study. What the cytokines did was to enhance the response mainly in the matched pairs, some almost to the same degree as in the third-party pairs. These data did contrast with the 3 HTdR incorporation data in the MLCs where the third party MLCs was consistently and considerably higher than the matched pairs. One must however remember that CD69 is a marker for activation and is not equivalent to the in vitro assessment of proliferation. The addition of cytokines, by amplifying minor antigenic differences might be sufficient to trigger a CD69 response, almost equivalent to a third-party response in some instances. What is clear though is that both CD69 expression and proliferation detected by 3 HTdR uptake do serve as markers for a specific alloreactive response.
This method of selective depletion has been shown to be effective in both mismatched pairs and in HLA-identical donor:recipient pairs. A logical extension would be the use of this method in haploidentical-related donors and in 1/2/3 antigen mismatched transplants. This would considerably widen the potential pool of donors available since in most cases, a haploidentical related donor is readily available. It would also allow for further sub-selection on the basis of age, CMV status and other important transplant variables. This will allow us to undertake 'intelligent' T cell depletion where the issue is no longer how many T cells can be removed from the graft but rather, how many can be retained without inducing GVHD.
